PUURS, Belgium (Reuters) – U.S. drugmaker Pfizer is ready to launch its respiratory syncytial virus (RSV) vaccine for both older adults and pregnant women in the U.S. and Europe this year, executives said on Thursday.
(Reporting by Maggie Fick; editing by Jason Neely)
